ARTICLE | Clinical News
AGS-16M8F: Phase I started
September 6, 2010 7:00 AM UTC
Astellas' Agensys Inc. subsidiary began an open-label, dose-escalation, U.S. Phase I trial to evaluate AGS-16M8F in about 50 patients. AGS-16M8F uses antibody-drug conjugate technology from Seattle ...